Key findings

Zilucoplan, an inhibitor of complement C5, is efficacious and safe for treating generalised myasthenia gravis, shows the phase 3 RAISE trial. Findings of the joint European, North American, and Japanese trial are reported in the journal Lancet Neurology .

Background

Existing and emerging treatments have limited efficacy and...